FDA Panel Approves OSI Pharmaceuticals' Anti-Cancer Drug Tarceva
Posted on: Friday, 16 September 2005, 21:00 CDT
OSI Pharmaceuticals got some good news late Tuesday when an advisory panel to the U.S. Food and Drug Administration voted to approve anti-cancer drug Tarceva to treat advanced pancreatic cancer.
The FDA's Oncologic Drug Advisory Committee voted 10-to-3 in favor of recommending approval of Tarceva to be used along with anti- cancer drug gemcitabine for advanced pancreatic cancer.
OSI said the FDA is expected to review the recommendation and decide whether to approve Tarceva by Nov. 2.
Tarceva is the first drug in a Phase III trial to have shown a significant improvement in overall survival when used with gemcitabine chemotherapy in advanced pancreatic cancer, according to OSI.
Tarceva is already approved to treat non-small cell lung cancer following chemotherapy.
Source: Long Island Business News
Related Articles
- Provides Insight into the Drug Pipeline Status of Pancreatic Cancer Drugs By Company and By Stage
- Array BioPharma Advances Breast Cancer Drug
- Roche Pancreatic Cancer Drug Approved in EU
- NICE Rejects Use of Cancer Drug Tarceva
- EntreMed Experimental Cancer Drug Shows Promise
- Neopharm Clears a Key Hurdle: Brain Cancer Drug Advances, Takes Stock Price With It
- New-Generation Drug OK'D to Treat Advanced Kidney Cancer
- Lung Cancer Drug Shown to Help Pancreatic Cancer Patients Live Longer
- Breast Cancer Drug Hailed As Greatest Advance in 30 Years Medical Experts Hail New Drug Treatment for Breast Cancer
 |
 |
User Comments (0)
RSS Feeds